Results for tag: "Kidney Transplantation Therapeutics"

Kidney transplantation is a surgical procedure to place a healthy kidney from a live or deceased donor into a person whose kidneys no longer function properly. Immunosuppressive drugs are an integral part of the kidney transplantation therapeutics market. These medications are essential to prevent the recipient's immune system from rejecting the new organ. The immunosuppressive drug regimen usually begins immediately after transplantation and continues for the lifetime of the transplanted organ. The therapy typically involves a combination of drugs, each with a specific mechanism of action, including calcineurin inhibitors, antiproliferative agents, corticosteroids, and mTOR inhibitors. The balance of these medications is crucial, as too much immunosuppression can lead to infection and cancer, while too little can result in organ rejection. Some prominent companies in the kidney transplantation therapeutics market include Pfizer Inc., Novartis AG, Astellas Pharma, and Bristol Myers Squibb. These organizations are engaged in the development, manufacturing, and marketing of immunosuppressive drug therapies. They invest in research and development activities to improve the efficacy and safety of these medications, aiming to enhance the quality of life for transplant recipients and reduce the complications associated with immunosuppression. Show Less Read more